Ausper Biopharma, Inc, a developer of drugs and vaccines for chronic hepatitis B virus (HBV) based in Hangzhou, has reportedly raised USD 16 million in a Pre-Series A financing round. The round was backed by InnoPinnacle Fund and angel investors. The proceeds will be used to advance global clinical studies for its small nucleic acid drugs aimed at curing HBV and to develop other pipelines.
Company Background and Platforms
Founded in 2019, Ausper Bio is known for its small nucleic acid drug platform for curing hepatitis B, therapeutic vaccine platform for hepatitis B, and a jointly developed nasal spray antibody platform, all of which are at the clinical filing stages. Current treatments for chronic HBV mainly include nucleoside analogues and interferon, which rarely achieve a functional cure. Ausper Bio’s small nucleic acid drugs can act on the mRNA of the hepatitis B virus through RNA interference technology, destroy its function as a post-transcriptional translation template, and prevent the synthesis of relevant viral proteins, thereby inhibiting the formation of viral particles.
Future Outlook
The Pre-Series A financing round underscores Ausper Biopharma’s commitment to advancing innovative treatments for chronic hepatitis B. By leveraging RNA interference technology, Ausper Bio aims to address significant unmet medical needs and improve outcomes for patients with chronic HBV.-Fineline Info & Tech
